Patents Assigned to Genentech
  • HER2 antibody composition
    Patent number: 7879325
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: February 1, 2011
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Martin Vanderlaan
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES
    Publication number: 20110020300
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a GCR gene using said pharmaceutical composition; and methods for inhibiting the expression of GCR in a cell.
    Type: Application
    Filed: May 14, 2010
    Publication date: January 27, 2011
    Applicant: GENENTECH, INC.
    Inventors: JACQUES BAILLY, AGNÈS BÉNARDEAU, BIRGIT BRAMLAGE, RAINER CONSTIEN, ANDREA FORST, MARKUS HOSSBACH, BRIGITTE SCHOTT
  • CRYSTALLIZATION OF ANTI-CD20 ANTIBODIES
    Publication number: 20110020322
    Abstract: The present invention relates generally to crystalline forms of anti-CD20 antibodies and purification of anti-CD20 antibodies involving crystallization.
    Type: Application
    Filed: June 17, 2010
    Publication date: January 27, 2011
    Applicant: Genentech, Inc.
    Inventors: James A. Wilkins, Shadia Abike Oshodi, Brian Lobo, Timothy Breece
  • ANTI-VEGF ANTIBODIES
    Publication number: 20110020346
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: July 27, 2010
    Publication date: January 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Methods for detecting inflammatory bowel disease
    Patent number: 7875431
    Abstract: The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: January 25, 2011
    Assignee: Genentech, Inc.
    Inventors: Lauri Diehl, Kenneth Flanagan, Lian Mo
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110015204
    Abstract: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 20, 2011
    Applicants: Array BioPharma, Inc., Genentech, Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • CRYSTAL STRUCTURE OF THE COMPLEX OF HEPATOCYTE GROWTH FACTOR BETA CHAIN WITH MET RECEPTOR AND METHODS OF USE
    Publication number: 20110012894
    Abstract: The disclosure provides a crystal structure of a complex of the HGF ?-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met receptor.
    Type: Application
    Filed: May 20, 2010
    Publication date: January 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Christian Wiesmann, Jennifer Stamos
  • ANTI-VEGF ANTIBODIES
    Publication number: 20110014198
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 15, 2010
    Publication date: January 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES
    Publication number: 20110008354
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: January 13, 2011
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, AVI J. ASHKENAZI, ANAN CHUNTHARAPAI, KYUNG JIN KIM
  • Treatment of Autoimmune Diseases
    Publication number: 20110008336
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • APO-2 RECEPTOR POLYPEPTIDES
    Publication number: 20110009599
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: March 1, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Treatment of Autoimmune Diseases
    Publication number: 20110008338
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008250
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Anti-PRO87299 antibodies
    Patent number: 7863422
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: January 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Hilary Clark, Daniel L. Eaton, Bernd Wranik, Wenjun Ouyang, Lino Gonzalez, Austin L. Gurney, Kelly Loyet
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Patent number: 7862817
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: January 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
    Publication number: 20100330083
    Abstract: A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution.
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventor: Charles P. SEMBA
  • NLRR-1 ANTAGONISTS AND USES THEREOF
    Publication number: 20100330082
    Abstract: NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.
    Type: Application
    Filed: October 1, 2008
    Publication date: December 30, 2010
    Applicant: GENENTECH INC.
    Inventors: Meredith Hazen, Jo-Anne S. Hongo, Victoria Smith, Susanna Stinson
  • OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20100331305
    Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Cuong Ly, Joseph P. Lyssikatos, Zhonghua Pei, Wendy Lee, Xianrui Zhao
  • POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
    Publication number: 20100331251
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: March 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo
  • METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES
    Publication number: 20100330096
    Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
    Type: Application
    Filed: September 7, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventor: Kyung Jin Kim